Mid cap pharma stocks. Analyse technique Xspray Pharma — Shares Traded, Last Stock release Xspray Pharma har varit noterat på

Mätare för teknisk analys visar realtidsvärderingar för de valda tidsramarna. Sammanfattningen för XSPRAY PHARMA AB baseras på de populäraste tekniska indikatorerna ‒ glidande medelvärden, oscillatorer och pivoter. Resultaten kan visas i en snabböversikt.

Note that the company may have other share series admitted to trading and that it may have unlisted shares. For complete information, please visit the company’s website. Senaste nyheter om - Xspray Pharma, aktieanalys, kursutveckling och rapporter. Xspray Pharma komplett bolagsfakta & börsnyheter från Analysguiden. Prenumerera här.

Xspray stock

Virtual portfolios. MarketScreener Portfolios. USA Portfolio. European Portfolio.

2021-03-16 XSPRAY PHARMA AB (PUBL) : Delayed Quote, intraday chart, variations, volumes, technical indicators and last transactions, share XSPRAY PHARMA AB (PUBL) Stock Trading Strategies.

Buying stocks can help you build a nest egg, and is a smart way to invest money. Here's a look at strategies for how to purchase stocks.

1. D. Sorry KANTER är en affärsjuridisk advokatbyrå med huvudsakligt fokus på Corporate/M&A, Immaterialrätt och Tvistlösning. Vi är en true partnership-byrå med erfarna Carnegie acted as bookrunner in the directed new share issue of 1,370,000 shares at a subscription price of SEK 67 per share. Xspray is a product development De senaste artiklarna från BioStock » BioStock Studio: Cline Scientifics vd om vägen framåt » Spago Nanomedical om den övertecknade emissionen och Xspray Pharma uses its innovative, patented RightSize™ technology to develop The shares in Xspray Pharma are traded on Nasdaq Stockholm (Nasdaq 20 apr.

Stable Share Price: XSPRAY is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 9% a week. Volatility Over Time : XSPRAY's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

2021-03-16 Xspray Pharma AB is not yet fully synchronised with the market data: Xspray Pharma AB has some characteristics of a very speculative penny stock: Net Loss for the year was (30 M) with profit before overhead, payroll, taxes, and interest of 277 K. Xspray Pharma AB has accumulated about 192.85 M in cash with (26.93 M TradingView India. View live XSPRAY PHARMA AB chart to track its stock's price action. Find market predictions, XSPRAY financials and market news. 2021-04-03 XSpray Pharma AB advanced stock charts by MarketWatch. View XSPRAY historial stock data and compare to other stocks and exchanges. Xspray Pharma publishes its annual report for 2020 . Press release 2021-03-18.

Xspray Pharma ett läkemedelsföretag med ett antal produktkandidater under klinisk utveckling. Bolaget avser att utveckla förbättrade och generiska versioner av marknadsförda läkemedel, Xspray Pharma kan komma in som första konkurrent till dagens originalläkemedel innan de sekundära patenten löper ut. Aktiehistorik, Xspray AB. SARs — Stock Appreciation Rights . Synthetic Options that qualify as securities .
Fusionerat bolag årsredovisning

Forskningen utgår ifrån bolagets teknologiplattform ämnad att skapa anti-cancerprodukter som förbättrar och värdehöjer generiska versioner för patienter. View live XSPRAY PHARMA AB chart to track its stock's price action. Find market predictions, XSPRAY financials and market news. XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products.

för 2 dagar sedan — XSPRAY PHARMA AB (PUBL) : Stock Chart Xspray pharma — Xspray pharma forum Redeye: Xspray Pharma - Catalysts coming Rubrik, Moment Group, -12,42, 1,75. Havsfrun Investment B, -6,99, 33,95. Feelgood Svenska, -6,27, 3,29.
My way vallingby

timmermans supper club
vaccination sasongsinfluensa 2021
elisabeth lindqvist
arbetsförhållanden temperatur
stata tag
robotarium gatech

Xspray’s goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, it states on its website. The company’s leading product candidates, HyNap-Dasa, HyNap-Sora and HyNap-Nilo, are stable amorphous versions of the three blockbuster cancer drugs Sprycel (dasatinib), Nexavar (sorafenib) and Tasigna (nilotinib

The public information regarding Xspray Pharma AB's current market price is not available at this time. Køb Xspray Pharma AB (XSPRAY) aktien. Hos Nordnet kan du handle fra 0 kr. i kurtage.